Scott Wilkie

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

Scott Wilkie, May CI van Schalkwyk, Steve Hobbs et al. · Journal of Clinical Immunology · 2012 · 480 citations

Breast Oncology, Medicine, Dual Targeting +6

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

Scott Wilkie, Gianfranco Picco, Julie Foster et al. · The Journal of Immunology · 2008 · 344 citations · Full text

Binding to serine 65‐phosphorylated ubiquitin primes Parkin for optimal <scp>PINK</scp> 1‐dependent phosphorylation and activation

Agne Kazlauskaite, R.J. Martinez-Torres, Scott Wilkie et al. · EMBO Reports · 2015 · 241 citations · Full text

Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4

Scott Wilkie, S. Burbridge, Laura Chiapero-Stanke et al. · Journal of Biological Chemistry · 2010 · 190 citations · Full text

Immunology, Il-4 Receptor Alpha, Immunologic Mechanism +16

Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?

Sjoukje J. C. van der Stegen, David M. Davies, Scott Wilkie et al. · The Journal of Immunology · 2013 · 128 citations

Cell Therapy, Therapeutic Opportunity, Adaptive Immune System +21